22 June 2023 
EMA/CHMP/257716/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Aquipta 
atogepant  
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Aquipta, 
intended for the prophylaxis of migraine. The applicant for this medicinal product is AbbVie Deutschland 
GmbH & Co. KG. 
Aquipta will be available as 10 mg and 60 mg tablets. The active substance of Aquipta is atogepant, an 
analgesic (ATC code: N02CD07) which works as a calcitonin gene-related peptide (CGRP) antagonist. The 
benefit of Aquipta is that it reduces the number of migraine days per month, as observed in two phase 3, 
randomised, placebo-controlled clinical trials in patients with episodic or chronic migraine The most 
common side effects are nausea, constipation and fatigue/somnolence.  
The full indication is: 
AQUIPTA is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per 
month. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
